Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Cullinan Oncology, Inc. (CGEM)
NASDAQ:AMEX Investor Relations:
investorshub.advfn.com/consolidated-gems-inc-cgem-26232
Company Research
Source: GlobeNewswire
Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily pretreated, all-comer population of patients with relapsed/refractory AML to be presented in oral presentation at ASH 2025 Company to share initial data for CLN-978, a CD19xCD3 bispecific T cell engager, in both SLE and RA in first half of 2026 Based on review of emerging clinical data, CLN-619 and CLN-617 programs discontinued Cash and investments of $475.5 million as of September 30, 2025; Runway into 2029 CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights and announced its financial results for the third quarter ended September 30, 2025. “Cullinan is strategically focusing resources and development efforts on sele
Show less
Read more
Impact Snapshot
Event Time:
CGEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGEM alerts
High impacting Cullinan Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CGEM
News
- Cullinan Therapeutics (NASDAQ:CGEM) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid LeukemiaGlobeNewswire
- Cullinan Therapeutics (NASDAQ:CGEM) had its "buy" rating reaffirmed by analysts at BTIG Research.MarketBeat
- Cullinan Therapeutics (NASDAQ:CGEM) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CGEM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Cullinan Therapeutics (NASDAQ:CGEM) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.MarketBeat
CGEM
Earnings
- 11/6/25 - Beat
CGEM
Sec Filings
- 11/25/25 - Form 4
- 11/24/25 - Form 144
- 11/21/25 - Form 8-K
- CGEM's page on the SEC website